Multiple Sclerosis Society of Great Britain and Northern Ireland Report issue

Foundation Phase 2

Organization Overview

First Clinical Trial
2011
NCT01451593
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2013

Timeline

NOW
  • Now

Active Ingredients

Drugs in Phase 2 Trials (2)

amiloride (midamor) (1 trial)

phenytoin (mesantoin) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Multiple Sclerosis (Phase 2)

Neuritis (Phase 2)

Optic Neuritis (Phase 2)

Sclerosis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 2
  • # of Trial APIs: 2